Medigene Ag

Welcome to the MediGene Full Year 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. Please note, this conference is being recorded. I would now like to hand over to your speaker today, Ms. Pamela Keck, Head of IR and Corporate Communications. Please go ahead.

Welcome everyone and thank you for joining us. With me today is Dr. Selvin Ho, CEO of MediGene. Today we announced financial results for the year ended December 31st, 2022. You can access the press release on the investor relations page of our website at MediGene.com. Before we get started, let's quickly run through the forward-looking statements. Please note that as part of our discussion today, management will be making forward-looking statements. Although we believe our expectations are based on reasonable assumptions, by their very nature, forward-looking statements involve risks and uncertainties and may be influenced by factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Any forward-looking statements made on the call reflect the knowledge and information available at the time of this call. The company undertakes no obligation to update forward-looking statements. With that, I'll hand the call over to Selvan.

Thank you, Pamela. Good morning, good afternoon, everyone, and thank you for joining MediGene's full-year 2022 earnings call. I'm excited to review the past year of accomplishments, as we continue the transition of MediGene and provide an outlook on all that we expect to achieve in 2023. Since joining the company as CEO in July 2022, I've been working diligently with the team to evaluate our corporate vision. And as a result of our work, we released our updated strategy in November of last year. I am proud to call MediGene a platform biotech company focused on developing differentiated T-cell receptor engineered T-cell, or TCRT for short, therapies for the treatment of multiple solid tumor indications in patients with high unmet medical needs. At the heart of our work is our extensive expertise in T-cell immunology and many years of development of a proprietary, innovative, end-to-end platform. MediGene's focus is to leverage this platform to build incremental differentiation of our TCRT therapies at multiple sequential stages of the drug discovery and development process, whilst continuously innovating the technologies within the platform. In the management of cancer, personalized medicines are and will continue to play an increasing role. Immuno-oncology cell therapies, such as TCRT therapies, are emerging as a novel class of treatment with clinical benefits being consistently demonstrated in treating solid tumors. Despite these advances, unmet needs clearly remain for further improvements, particularly in sustaining efficacy and with a lower risk of adverse side effects. Our end-to-end technology platform, built on these multiple, combinable product enhancements and development optimization technologies, allows us to identify and develop TCRT therapies for multiple solid tumor indications that we believe will be optimized for both safety and efficacy. We further believe this platform may allow us to create best-in-class TCRT therapies, ensuring that MediGene has a unique opportunity to make a real impact on the lives of cancer patients. To date, the robustness of our work has been scientifically validated through multiple partnerships. in which both potentially highly differentiated T cell receptors and novel individual platform technologies have been outlicensed from MediGene to our partners. Clinical validation of our platform also comes from the results of our phase one trial with MDG 1011 in patients with certain blood cancers.